Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03017235 · ClinicalTrials.gov registry record · Phase 3
A Study Comparing the Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Oral Solution With PREPOPIK® for Colon Cleansing in Preparation for Colonoscopy
A Phase 3 study, sponsored by Ferring Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 917
- Enrollment target
NCT03017235: Completed Phase 3 study, sponsored by Ferring Pharmaceuticals.
NCT03017235 is a Phase 3 study that has completed, run by Ferring Pharmaceuticals. The registered enrollment target is 917 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (19% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03017235, a Phase 3 study, has completed, sponsored by Ferring Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 917 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Oral Solution with PREPOPIK® for colon cleansing in adult subjects undergoing colonoscopy.
Primary Outcome
The efficacy of overall colon cleansing in terms of responders was measured by a blinded endoscopist using the Modified Aronchick Scale. Modified Aronchick scale is a 4-point scale that grades colon cleansing as Excellent (\>90% of mucosa seen, mostly liquid stool, minimal suctioning needed for adequate visualization), Good (\>90% of mucosa seen, mostly liquid stool, significant suctioning needed for adequate visualization), Fair (\>90% of mucosa seen, mixture of liquid and semisolid stool, coul
Interventions
- DRUG Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Oral Solution
- DRUG Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Powder
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 917 participants |
| Start Date | 2017-02-20 |
| Est. Completion | 2017-10-12 |
| Phase | Phase 3 |
What the finished NCT03017235 record still lists
NCT03017235 is an interventional study that assigns participants to a tested intervention. The registered 917 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (19% higher).
The record links to 0 conditions, and to 2 interventions - of which Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Oral Solution is the first listed.
NCT03017235 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03017235 about?
NCT03017235 is a clinical study titled "A Study Comparing the Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Oral Solution With PREPOPIK® for Colon Cleansing in Preparation for Colonoscopy". The purpose of this study is to compare the Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Oral Solution with PREPOPIK® for colon cleansing in adult subjects undergoing colonoscopy.
What is the current status of trial NCT03017235?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 917 participants. The study started on 2017-02-20. Estimated completion is 2017-10-12.
What interventions are being tested in trial NCT03017235?
The interventions under investigation include: Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Oral Solution (DRUG), Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Powder (DRUG).
Who is sponsoring clinical trial NCT03017235?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03017235's enrollment target sits among peer trials
917 347th of 2000 higher than 1,654 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05739955 · 918 participants · NA
Impact of Enhanced Daily Disinfection on Environmental Contamination in Hospital Rooms
- NCT04589845 · 920 participants · Phase 2
Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study
- NCT06109870 · 920 participants · NA
Prevención en Sus Manos: Feasibility of a Novel Community-Based Strategy to Improve Access to Cervical Cancer Screening
- NCT06957366 · 920 participants · NA
Perioperative Anticoagulant Use for Surgery Evaluation -2 (PAUSE-2) Study Patients Receiving a Direct Oral Anticoagulant (DOACs-Dabigatran, Rivaroxaban, Apixaban or Edoxaban) and Needing Elective High-Bleed-Risk Surgery or an Invasive Procedure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI